Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Exelixis, Inc.

Exelixis, Inc. (EXEL) Stock Overview

Explore Exelixis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EXEL●NASDAQ
HealthcareBiotechnology
$70.70
$0.12(0.17%)
U.S. Market opens in 3h 56m

Exelixis, Inc. (EXEL)

Meyka AI Score

Z

Key Financials

Market Cap17.8B
P/E Ratio20.39
EPS (TTM)$3.50
ROE0.46%
Fundamental Analysis

AI Price Forecasts

1 Month$73.54
3 Months$75.11
1 Year Target$59.89

EXEL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Exelixis, Inc. (NASDAQ: EXEL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, Exelixis, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EXEL on the NASDAQ shows an RSI of 66.05, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $59.89 for the NASDAQ listing.

Key metrics behind Exelixis, Inc.'s NASDAQ-traded stock include a P/E ratio of 20.39 and a market capitalization of 17.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of EXEL on the NASDAQ.

Price Performance (NASDAQ: EXEL)

1-Day Change
0.17%
5-Day Change
3.44%
1-Month Change
18.11%
3-Month Change
37.74%
6-Month Change
42.22%
Year-to-Date (YTD) Change
61.31%
1-Year Change
64.50%
3-Year Change
237.63%
5-Year Change
296.30%
All-Time (Max) Change
379.32%

Contact Information

https://www.exelixis.com
650 837 7000
1851 Harbor Bay Parkway, Alameda, CA, 94502

Company Facts

10,770 Employees
IPO DateApr 17, 2000
CountryUS
Actively Trading

Frequently Asked Questions